{"id":"NCT02562755","sponsor":"SillaJen, Inc.","briefTitle":"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone","officialTitle":"A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10","primaryCompletion":"2020-07","completion":"2020-07","firstPosted":"2015-09-29","resultsPosted":"2020-12-16","lastUpdate":"2020-12-16"},"enrollment":459,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":[{"type":"BIOLOGICAL","name":"Pexastimogene Devacirepvec (Pexa Vec)","otherNames":["JX-594"]},{"type":"DRUG","name":"Sorafenib","otherNames":["Nexavar"]}],"arms":[{"label":"Pexa-Vec followed by Sorafenib","type":"EXPERIMENTAL"},{"label":"Sorafenib","type":"ACTIVE_COMPARATOR"}],"summary":"This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.","primaryOutcome":{"measure":"Overall Response Rate (ORR)","timeFrame":"From date of randomization to the date of first documented radiographic tumor progression up to 53 months","effectByArm":[{"arm":"Pexa-Vec Followed by Sorafenib","deltaMin":19.2,"sd":null},{"arm":"Sorafenib","deltaMin":20.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":142,"countries":["United States","Australia","Canada","China","France","Germany","Hong Kong","Israel","Italy","New Zealand","Portugal","Singapore","South Korea","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":117,"n":218},"commonTop":["Diarrhoea","Pyrexia","Palmar plantar erythrodysaesthesia syndrome","Decreased appetite","Nausea"]}}